Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain- Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties (CROSBI ID 250241)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Gobec, Martina ; Tomašić, Tihomir ; Štimac, Adela ; Frkanec, Ruža ; Trontelj, Jurij ; Anderluh, Marko ; Mlinarič-Raščan, Irena ; Jakopin, Žiga
engleski
Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain- Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties
Muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, has long been known as the smallest fragment possessing adjuvant activity, on the basis of its agonistic action on the nucleotide-binding oligomerization domain- containing protein 2 (NOD2). There is a pressing need for novel adjuvants and NOD2 agonists provide an untapped source of potential candidates. Here, we report the design, synthesis and characterization of a series of novel acyl tripeptides. A pivotal structural element for molecular recognition by NOD2 has been identified, culminating in the discovery of compound 9, the most potent desmuramylpeptide NOD2 agonist to date. Compound 9 augmented pro- inflammatory cytokine release from human peripheral blood mononuclear cells in synergy with lipopolysaccharide. Furthermore, it was able to induce ovalbumin- specific IgG titers in a mouse model of adjuvancy. These findings provide deeper insights into the structural requirements of desmuramylpeptides for NOD2-activation and highlight the potential use of NOD2 agonists as adjuvants for vaccines.
Muramyl dipeptide, immunomodulator, desmuramylpeptide, NOD2 agonist, immunostimulant, adjuvant
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
61 (7)
2018.
2707-2724
objavljeno
0022-2623
1520-4804
10.1021/acs.jmedchem.7b01052